Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2026-09-17 16:06:23 ET · period of report 2026-09-15 · accession 0001628280-26-062490 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-09-17 16:06 | 2026-09-15 | ARQT | Welgus Howard G. | Dir | M - OptEx | $7.93 | +4,096 | 40.6K | +11% | +$32.5K |
| DT | 2026-09-17 16:06 | 2026-09-15 | ARQT | Welgus Howard G. | Dir | S - Sale+OE | $24.18 | -4,730 | 35.8K | -12% | -$114.4K |
| DMT | 2026-09-17 16:06 | 2026-09-15 | ARQT | Welgus Howard G. | Dir | M - OptEx | $0.00 | -4,096 | 18.0K | -19% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-15 | M | A | 822 | $6.52 | 37,297 | D | — | — | (F1) The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. |
| 2 | Common | Common Stock | 2026-09-15 | M | A | 1,019 | $7.51 | 38,316 | D | — | — | (F1) The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. |
| 3 | Common | Common Stock | 2026-09-15 | M | A | 2,255 | $8.63 | 40,571 | D | — | — | (F1) The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. |
| 4 | Common | Common Stock | 2026-09-15 | S | D | 4,730 | $24.18 | 35,841 | D | — | — | (F1) The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. |
| 5 | Derivative | Stock Option (right to buy) | 2026-09-15 | M | D | 822 | $0.00 | 6,574 | D | $6.52 · — to 2029-11-20 | 822 Common Stock | (F1) The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. (F2) The option is fully vested. |
| 6 | Derivative | Stock Option (right to buy) | 2026-09-15 | M | D | 1,019 | $0.00 | 8,144 | D | $7.51 · — to 2033-05-31 | 1,019 Common Stock | (F1) The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. (F2) The option is fully vested. |
| 7 | Derivative | Stock Option (right to buy) | 2026-09-15 | M | D | 2,255 | $0.00 | 18,032 | D | $8.63 · — to 2034-06-14 | 2,255 Common Stock | (F1) The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. (F2) The option is fully vested. |